Search the Newsreel

Central Garden (CENT) Upgraded to Buy: Here's Why

Central Garden (CENT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. …

Central Garden & Pet stock reports higher margins despite sales decline

Central Garden & Pet Company (CENT) Stock Price, News, Quote & History

Is Central Garden & Pet (CENTA) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Considering these trends, …

Ascentage Pharma Chairman Yang Dajun Spends Over HK$1.15 Million to Increase Stake by 38,600 Shares

Ascentage Pharma's Executive Director and Chairman, Yang Dajun, purchased 38,600 ordinary shares of the company between September 23 and 25, 2026, for approximately HK$1.1571 million. This transaction increased his total stake to 62.5703 million shares, representing about 16.69% of the company's issued share capital. …

Form 4 Central Garden & Pet Company For: 28 September By Investing.com

This article announces the filing of Form 4 for Central Garden & Pet Company on September 28. It provides a brief financial update showing CENT with a 0.43% gain. The piece itself is very short, primarily serving as an announcement, and includes no detailed …

A family trust distributed 1,000 shares of Central Garden & Pet (CENT) to a beneficiary.

William E. Brown, Chairman of Central Garden & Pet Co. (CENT), reported that a family Irrevocable Trust, where he and his spouse serve as co-trustees, distributed 1,000 shares of Class A Common Stock to a beneficiary on September 24, 2026. Following this transaction, the …

Ascentage Pharma Chairman Lifts Stake in Confidence-Building Share Purchase

Ascentage Pharma Trustee Buys Shares to Fund 2022 RSU Scheme

Central Garden & Pet (CENT) Stock Looks Hard To Call After A 24% Run

Central Garden & Pet (CENT) Could Be 26% Undervalued On Garden Leadership Change

Ascentage Pharma Group International (SEHK:6855) Ties Up With Peking University, Is The Upside Priced In?

Ascentage Pharma Group International (SEHK:6855) has partnered with Peking University for research in hematologic oncology, causing a 7.24% share price jump. Despite a recent surge, the company's valuation presents mixed signals, with some analyses suggesting it is 27% undervalued while others indicate a rich …

Central Garden & Pet Announces Garden Segment Leadership Transition

Central Garden & Pet Company announced a leadership transition in its Garden segment. J.D. Walker, President of Garden Consumer Products, will retire effective September 26, 2026, and Jason Barnes, Executive Vice President, will succeed him. Barnes will be responsible for sales, marketing, and service …

CENTA Q2 2026 Earnings: Narrow EPS Miss Keeps Shares Slightly Lower - Management Tone Analysis

Central Garden & Pet names Jason Barnes to lead garden segment By Investing.com

Central Garden & Pet Company announced that Jason Barnes will take over as the President of its Garden Consumer Products segment, succeeding J.D. Walker who is retiring. Barnes will be responsible for sales, marketing, and service across the Garden segment, as well as managing …

HK Stock Market Movements | Transcenta Holding -B (06628) surges over 24% as Chairman Qian Xueming increases stake; H1 out-licensing revenue rises

Centaurus Metals Limited(ASX: CTM) added to S&P Global BMI Index

Central Garden & Pet stock falls below 200-day line as earnings pressure lingers

Ascentage Pharma Group International reports 1H results

* Ascentage Pharma Group International press release [https://seekingalpha.com/filing/310075972] (AAPG [https://seekingalpha.com/symbol/AAPG]): 1H Revenue of RMB 302.2M. MORE ON ASCENTAGE PHARMA GROUP INTERNATIONAL * Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript [https://seekingalpha.com/article/4938839-ascentage-pharma-group-international-aapg-q2-2026-earnings-call-transcript] * Ascentage Pharma Group International 2026 Q2 - Results - Earnings …

Ascentage Pharma Trustee Buys Shares to Support 2022 RSU Incentive Scheme

Are Consumer Discretionary Stocks Lagging Central Garden & Pet (CENTA) This Year?

The Consumer Discretionary group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Central Garden (CENTA) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison …

Central Garden & Pet (CENT) Stock Looks Fairly Valued As Its 26% Run Continues

Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month Low - Here's What Happened

6855: Expanded Hematology Data And ATM Offering Will Drive Future Bullish Repricing

Ascentage Pharma Group International (6855) has seen its fair value target reset to HK$71.78, a decrease from HK$76.60, by analysts. This adjustment reflects updated assumptions including higher revenue growth expectations, a lower profit margin, and a more moderate future P/E estimate. Recent news for …

Ascentage Pharma Group International (NASDAQ: AAPG) Stock Price, News & Analysis

Could Centaurus Metals (ASX:CTM) Be the Next ASX Resources Stock to Break Out?

Central Garden & Pet (CENTA) Stock Analysis Report | Ratings, Financials & Performance

Ascentage Pharma (6855 HK): Trials Progress, Olverembatinib, Lisaftoclax Gain Momentum in 1H26

Central Garden & Pet (CENT) Lifts Profit Outlook As Valuation Debate Sharpens

Central Garden & Pet (CENT) held a special call to discuss its fiscal 2026 third quarter, highlighting lower reported net sales, a higher full year profit outlook, and an agreement to acquire 80% of European pet supplier TRIXIE. At a share price of $41.71, …

Is Central Garden & Pet (CENT) Undervalued As Higher Guidance And The TRIXIE Deal Reset Expectations?

Central Garden (CENT) Down 10.4% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for Central Garden (CENT). Shares have lost about 10.4% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next …

CENTA Q2 2026 Earnings: EPS Falls 1.45% Short of Consensus While Shares Edge Higher - Annual Earnings Summary

CENTA Q2 2026 Earnings: EPS Falls 1.45% Short of Consensus While Shares Edge Higher - Revenue Breakdown Analysis